Douglas Pharmaceuticals has opened a state-of-the-art $50 million research and development facility in West Auckland. The building is three stories tall, 4,500 sqm and employs over 100 people.
The family-owned firm is investing in the repurposing of existing drugs to treat a range of illnesses and is researching treatment for inflammatory bowel disease, cervical dysplasia and HIV.
The company works with university researchers and medical doctors from around the world.
“They translate this research into formulations and manage clinical studies that assess safety and effectiveness in a small number of patients. We will eventually out-licence those results to larger pharmaceuticals for commercialisation,” said Jeff Douglas, Managing Director.
“Our expertise is finding new uses for well-established medicines, and we are cutting our teeth with peptides and enzymes. We have a good success rate registering medicines with the United States FDA and European Union regulatory authorities and offer this service together with our formulation, clinical and medical affairs support services,” said Dr Peter Surman, Chief Scientific Officer.
